Latin, English, French, Spanish:

Recommended INN

Chemical name or description; Molecular formula; Graphic formula

DCI Recommandée

Nom chimique ou description; Formule brute; Formule développée

DCI Recomendada

Nombre químico o descripción; Fórmula empírica; Fórmula desarrollada

adargileukinum alfa

adargileukin alfa

[88-arginine]interleukin 2 (human clone pTIL2-21a) (partly glycosylated)

adargileukine alfa

[88-arginine]interleukine 2 humaine (clone pTIL2-21a) (en partie glycosylée)

adargileukina alfa

[88-arginina]interleukina 2 humana (clon pTIL2-21a) (parcialmente glicosilada)

C₆₉₅H₁₁₂₄N₁₈₀O₂₀₂S₇ (peptide)

alamifovirum

alamifovir

bis(2,2,2-trifluoroethyl) [(2-{2-amino-6-[(4-methoxyphenyl)sulfanyl]-9H-purin-9-yl}ethoxy)methyl]phosphonate

alamifovir

[[2-[2-amino-6-[(4-méthoxyphényl)sulfanyl]-9H-purin-9-yl]éthoxy]méthyl]phosphonate de bis(2,2,2-trifluoroéthyle)

alamifovir

[(2-{2-amino-6-[(4-metoxifenil)sulfanil]-9H-purin-9-il}etoxi)metil]fosfonato de bis(2,2,2-trifluoroetilo)

C₁₉H₂₀F₆N₅O₅ PS

aprinocarsenum

aprinocarsen

2'-deoxy-P -thioguanylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P -thiothymidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-P -thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')- 2'-deoxyadenosine

aprinocarsen

2'-désoxy-P-thioadénylyl-(5'→3')-2'-désoxy-P-thiocytidylyl-(5'→3')-P-thiothymidylyl-(5'→3')-P-thiothymidylyl-(5'→3')-P-thiothymidylyl-(5'→3')-2'-désoxy-P-thioguanylyl-(5'→3')-2'-désoxy-P-thioadénylyl-(5'→3')-2'-désoxy-P-thioguanylyl-(5'→3')-P-thiothymidylyl-(5'→3')-2'-désoxy-P-thioguanylyl-(5'→3')-2'-désoxy-P -thioguanylyl-(5'→3')-P-thiothymidylyl-(5'→3')-2'-désoxy-P-thiocytidylyl-(5'→3')-2'-désoxy-P-thioguanylyl-(5'→3')-2'-désoxy-P -thiocytidylyl-(5'→3')-P-thiothymidylyl-(5'→3')-2'-désoxy-P-thiocytidylyl-(5'→3')-P-thiothymidylyl-(5'→3')-P-thiothymidylyl-(5'→3')-2'-désoxyguanosine

aprinocarseno

2'-desoxi-P-tioadenilil-(5'→3')-2'-desoxi-P -tiocitidilil-(5'→3')-P-tiotimidilil-(5'→3')-P -tiotimidilil-(5'→3')-P-tiotimidilil-(5'→3')-2'-desoxi-P-tioguanilil-(5'→3')-2'-desoxi-P -tioadenilil-(5'→3')-2'-desoxi-P-tioguanilil-(5'→3')-P-tiotimidilil-(5'→3')-2'-desoxi-P-tioguanilil-(5'→3')-2'-desoxi-P-tioguanilil-(5'→3')-P-tiotimidilil-(5'→3')-2'-desoxi-P-tiocitidilil-(5'→3')-2'-desoxi-P-tioguanilil-(5'→3')-2'-desoxi-P-tiocitidilil-(5'→3')-P-tiotimidilil-(5'→3')-2'-desoxi-P-tiocitidilil-(5'→3')-P-tiotimidilil-(5'→3')-P-tiotimidilil-(5'→3')-2'-desoxiguanosina

C₁₉₆H₂₄₉N₆₈O₁₀₅P₁₉S₁₉

belimumabum

belimumab

immunoglobulin G1, anti-(human cytokine BAFF) (human monoclonal LymphoStat-B heavy chain), disulfide with human monoclonal LymphoStat-B λ-chain, dimer

bélimumab

immunoglobuline G1, anti-(cytokine BAFF humaine); dimère du disulfure entre la chaîne lourde et la chaîne λ de l'anticorps monoclonal humain LymphoStat-B

belimumab

immunoglobulina G1, anti-(citoquina BAFF humana); dímero del disulfuro entre la cadena pesada y la cadena λ del anticuerpo monoclonal humano LymphoStat-B

cantuzumabum mertansinum

cantuzumab mertansine

immunoglobulin G1, anti-(mucin CanAg) (human-mousemonoclonal C242 heavy chain), disulfide with human-mousemonoclonal C242 light chain, dimer, conjugate at the 6-aminogroups of four lysine residues forming an amide bond with (4RS)- 4-[(3-{[(1S)-2-{[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-dimethoxy-2,5,9,16-tetramethyl-8,23-dioxo-4,24-dioxa-9,22-diazatetracyclo[19.3.1.1^10,14.0^3,5]hexacosa-10,12,14(26),16,18-pentaen-6-yl]oxy}-1-methyl-2-oxoethyl]=methylamino}-3-oxopropyl)disulfanyl]pentanoyl groups

cantuzumab mertansine

immunoglobuline G1, anti-(mucin CanAg); dimère du disulfureentre la chaîne lourde et la chaîne légère de l'anticorps monoclonalde souris C242 humanisé dont les groupes 6-amino de quatrelysines sont amidifiés par l'acide (4RS)-4-[[3-[[(1S)- 2-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-chloro-21-hydroxy-12,20-diméthoxy-2,5,9,16-tétraméthyl-8,23-dioxo-4,24-dioxa-9,22-diazatétracyclo[19.3.1.1^10,14.0^3,5]hexacosa-10,12,14(26),16,18-pentaén-6-yl]oxy]-1-méthyl-2-oxoéthyl]= méthylamino]-3-oxopropyl]disulfanyl]pentanoïque

cantuzumab mertansina

inmunoglobulina G1, anti-(mucina CanAg); dímero del disulfuroentre la cadena pesada y la cadena ligera del anticuerpomonoclonal humanizado de ratón C242 en el que los grupos6-amino de cuatro lisinas están amidificados por ácido (4RS)- 4-[[3-[[(1S)-2-[[(1S,2R,3S,5S,6S,16E,18E,20R,21S)-11-cloro-21-hidroxi-2,5,9,16-tetrametil -12,20-dimetoxi-4,24-dioxa-8,23-dioxo-9,22-diazatetraciclo[19.3.1.1^10,14.0^3,5]hexacosa-10,12,14(26),16,18-pentaen-6-il]oxi]-1-metil-2-oxoetil]metilamino]-3-oxopropil]disulfanil]pentanoico

cimicoxibum

cimicoxib

4-[4-chloro-5-(3-fluoro-4-methoxyphenyl)-1H-imidazol-1-yl]benzenesulfonamide

cimicoxib

4-[4-chloro-5-(3-fluoro-4-méthoxyphényl)-1H-imidazol-1-yl]benzènesulfonamide

cimicoxib

4-[4-cloro-5-(3-fluoro-4-metoxifenil)-1H-imidazol-1-il]bencenosulfonamida

C₁₆H₁₃ClFN₃O₃S

dabuzalgronum

dabuzalgron

N-{6-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)methoxy]-2-methylphenyl}methanesulfonamide

dabuzalgron

N-[6-chloro-3-[(4,5-dihydro-1H-imidazol-2-yl)méthoxy]-2-méthylphényl]méthanesulfonamide

dabuzalgrón

N-{6-cloro-3-[(4,5-dihidro-1H-imidazol-2-il)metoxi]-2-metilfenil}metanosulfonamida

C₁₂H₁₆ClN₃O₃S

dacinostatum

dacinostat

(2E)-N-hydroxy-3-[4-({(2-hydroxyethyl)[2-(1H-indol-3-yl)ethyl]amino}methyl)phenyl]propenamide

dacinostat

(2E)-N-hydroxy-3-[4-[[(2-hydroxyéthyl)[2-(1H-indol-3-yl)éthyl]amino]méthyl]phényl]prop-2-énamide

dacinostat

(2E)-N-hidroxi-3-[4-({(2-hidroxietil)[2-(1H-indol-3-il)etil]amino}metil)fenil]propenamida

C₂₂H₂₅N₃O₃

dalbavancinum

dalbavancin

5,31-dichloro-38-de(methoxycarbonyl)-7-demethyl-19-deoxy-56-O-[2-deoxy-2-[(10-methylundecanoyl)amino]- ß-D-glucopyranuronosyl]- 38-[[3-(dimethylamino)propyl]carbamoyl]-42-O-a-D-mannopyranosyl-15-Nmethyl(ristomycin A aglicone) (main component)

dalbavancine

acide 2-désoxy-1-O-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dichloro-38-[[3-(diméthylamino)propyl]carbamoyl]-6,11,34,40,44-pentahydroxy-42-(a-D-mannopyranosyloxy)-15-(méthylamino)-2,16,36,50,51,59-hexaoxo-2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tétradécahydro-20,23:30,33-diéthéno-3,18:35,48-bis(iminométhano)-1H,15H-4,8:10,14:25,28:43,47-tétraméthéno-34H-[1,14,6,22]dioxadiazacyclooctacosino[4,5-m][10,2,16]= benzoxadiazacyclotétracosén-56-yl]-2-[(10-méthylundécanoyl)= amino]-ß-D-glucopyranuronique (composant majeur)

dalbavancina

ácido 1-O-[(3S,15R,18R,34R,35S,38S,48R,50aR)-5,31-dicloro-38-[[3-(dimetilamino)propil]carbamoil]-6,11,34,40,44-pentahidroxi-42-(a-D-manopiranosiloxi)-15-(metilamino)-2,16,36,50,51,59-hexaoxo-2,3,16,17,18,19,35,36,37,38,48,49,50,50a-tetradecahidro-20,23:30,33-dieteno-3,18:35,48-bis(iminometano)-1H,15H-4,8:10,14:25,28:43,47-tetrameteno-34H-[1,14,6,22]dioxadiazaciclooctacosino[4,5-m][10,2,16]= benzoxadiazaciclotetracosen-56-il]-2-[(10-metilundecanoil)amino]-2-desoxi-ß-D -glucopiranurónico (componente principal)

C₈₈-H₁₀₀-Cl₂-N₁₀-O₂₈

deligoparinum natricum

deligoparin sodium

sodium salt of depolymerised heparin obtained by a controlled chemical process based on generation of free radicals by means of metal ions and hydrogen peroxide. The heparin starting material is obtained from porcine intestinal mucosa. The process results in oligosaccharide fragments of heparin of varying lengths. The average relative molecular mass is about 3200 Daltons, ranging from2250 to 3850 Daltons. The degree of sulfation is approximately 2.5 sulfate residues per disaccharide unit.

déligoparine sodique

sel de sodium d'héparine de basse masse moléculaire obtenue par par dépolymérisation à l'aide de radicaux libres (générés par des ions métalliques et du peroxyde d'hydrogène) d'héparine de muqueuse intestinale de porc. La majorité des composants présentent une structure acide 2-O-sulfo-α-D-glucopyranosuronique à l'extrémité non réductrice et une structure 2-désoxy-6-O-sulfo-2-(sulfoamino)-D-glucopyranose à l'extrémité réductrice de leur chaîne; la masse moléculaire relative moyenne est voisine de3200 (2250 à 3850); le degré de sulfatation est voisin de 2,5 par unité disaccharide.

deligoparina sódica

sal sódica de una heparina de baja masa molecular que se obtiene de la heparina de la mucosa intestinal porcina por despolimerización por radicales libres, generados por iones metálicos y peróxido de hidrógeno; la mayoría de los componentes tienen una estructura de ácido 2- O -sulfo-α-D-glucopiranosurónico en el extremo no-reductor de la cadena y una estructura 2-desoxy-6-O-sulfo-2-(sulfoamino)-D-glucopiranosa en el reductor; la masa molecular media oscila entre 2250 y 3850, con un valor característico de unos 3200; el grado de sulfatación es alrededor de 2,5 por unidad de disacárido.

desvenlafaxinum

desvenlafaxine

4-[(1RS)-2-(dimethylamino)-1-(1-hydroxycyclohexyl)ethyl]phenol

dèsvenlafaxine

4-[(1RS)-2-(diméthylamino)-1-(1-hydroxycyclohexyl)éthyl]phénol

desvenlafaxina

4-[(1RS)-2-(dimetilamino)-1-(1-hidroxiciclohexil)etil]fenol

C₁₆H₂₅NO₂

diboterminum alfa

dibotermin alfa

human recombinant bone morphogenic protein-2 (hrBMP-2)

dibotermine alfa

protéine-2 humaine recombinante morphogénique de l'os (PMOrh-2)

dibotermina alfa

proteína-2 humana recombinante morfogénica de hueso (PMOrh-2)

[C₅₇₁H₈₈₆N₁₆₀O₁₆₄S₉]₂

diquafosolum

diquafosol

P¹,P⁴-bis(5'-uridyl) tetrahydrogen tetraphosphate

diquafosol

uridine(5')tétraphospho(5')uridine

dicuafosol

tetrahidrógenotetrafosfato de P¹,P⁴-bis(5'-uridilo)

C₁₈H₂₆N₄O₂₃P₄

disermolidum

disermolide

(3Z,5S,6S,7S,8R,9S,11Z,13S,14S,15S,16Z,18S)-8,14,18-trihydroxy-19-[(2S,3R,4S,5R)-4-hydroxy-3,5-dimethyl-6-oxotetrahydro-2H-pyran-2-yl]-5,7,9,11,13,15- hexamethylnonadeca-1,3,11,16-tetraen-6-yl carbamate

disermolide

carbamate de (1S,2S,3R,4S,6Z,8S,9S,10S,11Z,13S)-3,9,13-trihydroxy-14-[(2S,3R,4S,5R)-4-hydroxy-3,5-diméthyl-6-oxotétrahydro-2H-pyran-2-yl]-2,4,6,8,10-pentaméthyl-1-[(1S,2Z)-1-méthylpenta-2,4-diényl]tétradéca-6,11-diényle

disermolida

carbamato de (3Z,5S,6S,7S,8R,9S,11Z,13S,14S,15S,16Z,18S)-8,14,18-trihidroxi-19-[(2S,3R,4S,5R)-4-hidroxi-3,5-dimetil-6-oxotetrahidro-2H-piran-2-il]-5,7,9,11,13,15-hexametilnonadeca-1,3,11,16-tetraen-6-ilo

C₃₃H₅₅NO₈

edifoligidum

edifoligide

duplex of 2'-deoxy-P-thiocytidylyl-(3'→5')-P -thiothymidylyl-(3'→5')-2'-deoxy-P -thioadenylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P -thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxyguanosine and 2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thiocytidylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioguanylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-2'-deoxy-P-thioadenylyl-(3'→5')-thymidine

édifoligide

2'-désoxy-P-thiocytidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-2'-désoxy-P -thioguanylyl-(3'→5')-2'-désoxy-P-thioadénylyl-(3'→5')-P -thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-P-thiothymidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P-thiocytidylyl-(3'→5')-2'-désoxy-P -thiocytidylyl-(3'→5')-2'-désoxy-P-thioguanylyl-(3'→5')-2'-désoxy-P -thiocytidylyl-(3'→5')-2'-désoxyguanosine et P-thiothymidylyl-(5'→3')-2'-désoxy-P-thioadénylyl-(5'→3')-2'-désoxy-P -thioadénylyl-(5'→3')-2'-désoxy-P-thioadénylyl-(5'→3')-2'-désoxy-P -thioguanylyl-(5'→3')-2'-désoxy-P-thioguanylyl-(5'→3')-2'-désoxy-P -thioguanylyl-(5'→3')-2'-désoxy-P-thiocytidylyl-(5'→3')-2'-désoxy-P -thioguanylyl-(5'→3')-2'-désoxy-P-thiocytidylyl-(5'→3')-2'-désoxy-P -thiocytidylyl-(5'→3')-P-thiothymidylyl-(5'→3')-2'-désoxy-P-thioadénylyl-(5'→3')-2'-désoxyguanosine partiellement complémentaires

edifoligida

2'-desoxi-P-tiocitidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P-tioadenilil-(3'→5')-2'-desoxi-P -tioguanilil-(3'→5')-2'-deoxi-P-tioadenilil-(3'→5')-P-tiotimidilil-(3'→5')-P -tiotimidilil-(3'→5')-P-tiotimidilil-(3'→5')-2'-desoxi-P -tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxi-P-tioguanilil-(3'→5')-2'-desoxi-P-tiocitidilil-(3'→5')-2'-desoxiguanosina y P-tiotimidilil-(5'→3')-2'-desoxi-P -tioadenilil-(5'→3')-2'-desoxi-P-tioadenilil-(5'→3')-2'-desoxi-P -tioadenilil-(5'→3')-2'-desoxi-P-tioguanilil-(5'→3')-2'-desoxi-P -tioguanill-(5'→3')-2'-disoxi-P-tioguanilil-(5'→3')-2'-desoxi-P -tiocitidilil-(5'→3')-2'-desoxi-P-tioguanilil-(5'→3')-2'-desoxi-P -tiocitidilil-(5'→3')-2'-desoxi-P-tiocitidilil-(5'→3')-P-tiotimidilil-(5'→3')-2'-desoxi-P-tioadenilil-(5'→3')-2'-desoxiguanosina parcialmente complementario

edotecarinum

edotecarin

12-ß-D-glucopyranosyl-2,10-dihydroxy-6-[[2-hydroxy-1-(hydroxymethyl)ethyl]amino]-12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione

édotécarine

12-ß-D-glucopyranosyl-2,10-dihydroxy-6-[[2-hydroxy-1-(hydroxyméthyl)éthyl]amino]-12,13-dihydro-6H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7-dione

edotecarina

12-ß-D-glucopiranosil-2,10-dihidroxi-6-[[2-hidroxi-1-(hidroximetil)etil]amino]-12,13-dihidro-6H-indolo[2,3-a]pirrolo=[3,4-c]carbazol-5,7-diona

C₂₉H₂₈N₄O₁₁

edratidum

edratide

glycyl-L-tyrosyl-L -tyrosyl-L -tryptophyl-L -seryl-L-tryptophyl-L-isoleucyl- L-arginyl-L-glutaminyl-L-prolyl-L -prolylglycyl-L-lysylglycyl-L-glutamyl- L-glutamyl-L-tryptophyl-L -isoleucylglycine

édratide

glycyl-L-tyrosyl-L -tyrosyl-L -tryptophyl-L -séryl-L-tryptophyl-L-isoleucyl- L-arginyl-L-glutaminyl-L-prolyl-L -prolyl-glycyl-L-lysyl-glycyl- L-glutamyl-L-glutamyl-L-tryptophyl-L-isoleucyl-glycine

edratida

glicil-L-tirosil-L-tirosil-L -triptofil-L-seril-L -triptofil-L-isoleucil-L-arginil-L-glutaminil-L-prolil-L-prolilglicil-L-lisilglicil-L-glutamil-L-glutamil- L-triptofil-L-isoleucilglicina

C₁₁₁H₁₄₉N₂₇O₂₈

elsilimomabum

elsilimomab

immunoglobulin G1, anti-(human interleukin 6) (mouse monoclonal B-E8 heavy chain), disulfide with mouse monoclonal B-E8 κ-chain, dimer

elsilimomab

immunoglobuline G1, anti-(interleukine 6 humaine); dimère du disulfure entre la chaîne lourde et la chaîne κ de l'anticorps monoclonal de souris B-E8

elsilimomab

inmunoglobulina G1, anti-(interleuquina 6 humana); dímero del disulfuro entre la cadena pesada y la cadena κ del anticuerpo monoclonal de ratón B-E8

elvucitabinum

elvucitabine

4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxymethyl)-2,5-dihydro-2-furyl]pyrimidin-2(1H)-one

elvucitabine

4-amino-5-fluoro-1-[(2S,5R)-5-(hydroxyméthyl)-2,5-dihydrofuran-2-yl]pyrimidin-2(1H)-one

elvucitabina

4-amino-5-fluoro-1-[(2S,5R)-5-(hidroximetil)-2,5-dihidro-2-furil]pirimidin-2(1H)-ona

C₉H₁₀FN₃O₃

epitumomabum cituxetanum

epitumomab cituxetan

Conjugate of 4-{(2RS)-2-[bis(carboxymethyl)amino]-3-({2-[bis(carboxymethyl)amino]ethyl}(carboxymethyl)amino)propyl} phenyl isothiocyanate forming a thiourea with the 6-amino of a lysine of immunoglobulin G1, anti-(human episialin) (mouse monoclonal HMFG-1 γ1-chain), disulfide with mouse monoclonal HMFG-1 light chain, dimer

épitumomab cituxétan

dérivé de la thiourée produite par réaction de l'isothiocyanate de4-[(2RS)-2-[bis(carboxyméthyl)amino]-3-[[2-[bis(carboxyméthyl)= amino]éthyl](carboxyméthyl)amino]propyl]phényle avec le 6-amino d'une lysine de l'immunoglobuline G1, anti-(human episialin); dimère du disulfure entre la chaîne γ1 et la chaîne légère de l'anticorps monoclonal de souris HMFG-1

epitumomab cituxetán

derivado de la tiourea producido por reacción del isotiocianato de4-[(2RS)-2-[bis(carboximetil)amino]-3-[[2-[bis(carboximetil)amino]etil] (carboximetil)amino]propil]fenil con el6-amino de una lisina de la inmunoglobulina G1, anti-(episialina humana); dímero del disulfuro entre la cadena γ1 y la cadena ligera del anticuerpo monoclonal de ratón HMFG-1

eptoterminum alfa

eptotermin alfa

human recombinant bone morphogenetic protein 7 (hrBMP-7) or osteogenic protein-1 (OP-1)

eptotermine alfa

protéine-7 humaine recombinante morphogénique de l'os (PMOrh-7) ou protéine-1 osteogénique (PO-1)

eptotermina alfa

proteína-7 humana recombinante morfogénicas de hueso (PMOrh-7) o proteína-1 osteogénica (PO-1)

[C₆₈₃H₁₀₆₁N₁₉₇O₂₀₈S₁₀]₂

exatecanum alideximerum

exatecan alideximer

exatecan linked via the tetrapeptide (glycylglycyl- L-phenylalanylglycyl) to poly[oxy(2-hydroxymethylethylene)oxy=(hydroxymethylmethylene)] partly O-substituted with carboxymethyl groups with some carboxy groups amide linked to the tetrapeptide.

exatécan alideximer

exatécan lié par une chaîne tétrapeptidique (glycylglycyl- L-phénylalanylglycyl) à des éthers carboxyméthyliques de poly[oxy(2-hydroxyéthylidène)oxy[1-(hydroxyméthyl)éthylène]]

exatecán alidexímero

exatecán ligado por una cadena tetrapeptídica (glicilglicil- L-fenilalanilglicil) a éteres carboximetílicos de poli[oxi-(2-hidroxietilideno)oxi[1-(hidroximetil)etileno]]

exenatidum

exenatide

L-histidylglycyl-L-glutamylglycyl-L-threonyl-L-phenylalanyl-L-threonyl-L-seryl-L-aspartyl-L -leucyl-L -seryl-L-lysyl-L -glutaminyl-L-methionyl-L-glutamyl-L-glutamyl-L-glutamyl-L -alanyl-L -valyl-L-arginyl-L-leucyl- L-phenylalanyl-L-isoleucyl-L -glutamyl-L-tryptophyl-L -leucyl-L-lysyl- L-asparaginylglycylglycyl-L -prolyl-L-seryl-L-serylglycyl-L -alanyl- L-prolyl-L-prolyl-L -prolyl-L-serinamide

exénatide

exendine 4 (Heloderma suspectum), synthétique

exenatida

L-histidilglicil-L-glutamilglicil-L-treonil-L-fenilalanil-L-treonil-L-seril-L-aspartil-L-leucil-L-seril-L -lisil-L-glutaminil-L-metionil-L-glutamil-L-glutamil-L-glutamil-L-alanil-L-valil-L-arginil-L-leucil-L-fenilalanil- L-isoleucil-L -glutamil-L-triptofil-L -leucil-L-lisil-L -asparaginilglicilglicil-L-prolil-L-seril-L -serilglicil-L-alanil-L-prolil-L-prolil-L-prolil-L-serinamida

C₁₈₄H₂₈₂N₅₀O₆₀S

firocoxibum

firocoxib

3-(cyclopropylmethoxy)-5,5-dimethyl-4-[4-(methylsulfonyl)= phenyl]furan-2(5H)-one

firocoxib

3-(cyclopropylméthoxy)-5,5-diméthyl-4-[4-(méthylsulfonyl)= phényl]furan-2(5H)-one

firocoxib

3-(ciclopropilmetoxi)-5,5-dimetil-4-[4-(metilsulfonil)fenil]furan-2(5H)-ona

C₁₇H₂₀O₅S

fispemifenum

fispemifene

2-(2-{4-[(1Z)-4-chloro-1,2-diphenylbut-1-enyl]phenoxy}=ethoxy)ethanol

fispémifène

2-[2-[4-[(1Z)-4-chloro-1,2-diphénylbut-1-ényl]phénoxy]=éthoxy]éthanol

fispemifeno

2-(2-{4-[(1Z)-4-cloro-1,2-difenilbut-1-enil]fenoxi}etoxi)etanol

C₂₆H₂₇ClO₃

fluoresceinum lisicolum

fluorescein lisicol

N⁶-({3',6'-dihydroxy-3-oxospiro[isobenzofuran-1(3H),9'-xanthen]-5-yl}thiocarbamoyl)-N²-(3α,7α,12α-trihydroxy-5β-cholan-24-oyl)-L-lysine

fluorescéine lisicol

acide (2S)-6-[[(3',6'-dihydroxy-3-oxospiro[isobenzofurane-1(3H),9'-[9H]xanthén]-5-yl)thiocarbamoyl]amino]-2-[(3α,7α,12α- trihydroxy-5β-cholan-24-oyl)amino]pentanoïque

fluoresceina lisicol

ácido 5-[({(5S)-5-carboxi-5-[(3α,7α,12α-trihidroxi-5β-colan-24-oil)amino]pentil}tiocarbamoil)amino]-2-(6-hidroxi-3-oxo-3H-xanten-9-il)benzoico

C₅₁H₆₃N₃O₁₁S

freselestatum

freselestat

2-[5-amino-6-oxo-2-phenylpyrimidin-1(6H)-yl]-N-[(1RS)-1-(5-tert-butyl-1,3,4-oxadiazol-2-yl)-3-methyl-1-oxobutan-2-yl]acetamide

frésélestat

2-(5-amino-6-oxo-2-phénylpyrimidin-1(6H)-yl)-N-[(1RS)-1-[[5-(1,1-diméthyléthyl)-1,3,4-oxadiazol-2-yl]carbonyl]-2-méthylpropyl]=acétamide

freselestat

2-[5-amino-6-oxo-2-fenilpirimidin-1(6H)-il]-N-[(1RS)-1-(5-terc-butil-1,3,4-oxadiazol-2-il)-3-metil-1-oxobutan-2-il]acetamida

C₂₃H₂₈N₆O₄

galiximabum

galiximab

immunoglobulin G1, anti-(human CD80 (antigen)) (human-Macaca irus monoclonal IDEC-114 heavy chain), disulfide with human-Macaca irus monoclonal IDEC-114 λ chain, dimer

galiximab

immunoglobuline G1, anti-(antigène CD80 humain), dimère du disulfure entre la chaîne λ et la chaîne lourde de l’anticorps monoclonal chimérique homme- macaque (Macaca irus) IDEC-114

galiximab

inmunoglobulina G1, anti-(antígeno CD80 humano), dímero del disulfuro entre la cadena λ y la cadena pesada del anticuerpo monoclonal quimérico hombre-macaco (Macaca irus) IDEC-114

hemoglobinum raffimerum

hemoglobin raffimer

The polyaldehyde [(2R,4S,6R,8R,11S,13R)-1,14-dihydroxy-4-hydroxymethyl-3,5,7,10,12-pentaoxatetradecane-2,4,6,8,11,13-hexacarbaldehyde] derived from raffinose [β-D-fructofuranosyl α-D-galactopyranosyl-(1→6)-α-D-glucopyranoside] by treatment with sodium periodate is reacted with human hemoglobin A₀ at the2,3-DPG binding pocket. Both intermolecular and intramolecular crosslinking occurs. This product is reduced to generate covalent amine bonds with >95% crosslinked hemoglobin of which about 55% is polymerised.

hémoglobine raffimer

hémoglobine stabilisée et partiellement polymérisée, obtenue parréduction du produit de la réaction du (2R,4S,6R,8R,11S,13R)-1,14-dihydroxy-4-(hydroxyméthyl)-3,5,7,10,12-pentaoxatétradécane-2,4,6,8,11,13-hexacarbaldéhyde (obtenu par oxydation periodique du rafinose) avec l'hémoglobine humaine

hemoglobina rafímero

hemoglobina estabilizada y parcialmente polimerizada, obtenida por reducción del producto de la reacción del (2R,4S,6R,8R,11S,13R)- 1,14-dihidroxi-4-(hidroximetil)-3,5,7,10,12-pentaoxatetradecano-2,4,6,8,11,13-hexacarbaldehído (obtenido por oxidación periodica de la rafinosa) con la hemoglobina humana

icofungipenum

icofungipen

(1R,2S)-2-amino-4-methylenecyclopentane-1-carboxylic acid

icofungipen

(-)-acide (1R,2S)-2-amino-4-méthylènecyclopentanecarboxylique

icofungipeno

(-)-ácido (1R,2S)-2-amino-4-metilenociclopentanocarboxílico

C₇H₁₁NO₂

icrocaptidum

icrocaptide

glycyl-N²-ethyl-L-lysyl-L -prolyl-L-arginine

icrocaptide

glycyl-(N²-éthyl-L -lysyl)-L -prolyl-L-arginine

icrocaptida

glicil-(N²-etil-L -lisil)-L-prolil-L-arginina

C₂₁H₄₀N₈O₅

iferanserinum

iferanserin

(E)-2'-{2-[(2S)-1-methyl-2-piperidyl]ethyl}cinnamanilide

iféransérine

(-)-(2E)-N-[2-[2-[(2S)-1-méthylpipéridin-2-yl]éthyl]phényl]-3-phénylprop-2-énamide

iferanserina

(-)-(2E)-N-(2-{2-[(2S)-1-metilpiperidin-2-il]etil}fenil)-3-fenilprop-2-enamida

C₂₃H₂₈N₂O

istradefyllinum

istradefylline

8-[(E)-2-(3,4-dimethoxyphenyl)vinyl]-1,3-diethyl-7-methyl-3,7-dihydro-1H-purin-2,6-dione

istradéfylline

8-[(E)-2-(3,4-diméthoxyphényl)éthényl]-1,3-diéthyl-7-méthyl-3,7-dihydro-1H-purin-2,6-dione

istradefilina

8-[(E)-2-(3,4-dimetoxifenil)vinil]-1,3-dietil-7-metil-3,7-dihidro-1H-purin-2,6-diona

C₂₀H₂₄N₄O₄

ixabepilonum

ixabepilone

(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-17-oxa-4-azabicyclo[14.1.0]heptadecane-5,9-dione

ixabépilone

(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentaméthyl-3-[(1E)-1-méthyl-2-(2-méthylthiazol-4-yl)éthényl]-17-oxa-4-azabicyclo[14.1.0]heptadécane-5,9-dione

ixabepilona

(1S,3S,7S,10R,11S,12S,16R)-7,11-dihidroxi-8,8,10,12,16-pentametil-3-[(1E)-1-(2-metil-1,3-tiazol-4-il)prop-1-en-2-il]-17-oxa-4-azabiciclo[14.1.0]heptadecano-5,9-diona

C₂₇H₄₂N₂O₅S

ladostigilum

ladostigil

(3R)-3-(prop-2-ynylamino)indan-5-yl ethyl(methyl)carbamate

ladostigil

éthylméthylcarbamate de (3R)-3-(prop-2-ynylamino)-2,3-dihydro-1H-indén-5-yle

ladostigilo

etilmetilcarbamato de (3R)-3-(prop-2-inilamino)indan-5-ilo

C₁₆H₂₀N₂O₂

lapatinibum

lapatinib

N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methylsulfonyl)= ethyl]amino}methyl)-2-furyl]quinazolin-4-amine

lapatinib

N-[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furyl]quinazolin-4-amine

lapatinib

N-[3-cloro-4-(3-fluorobenciloxi)fenil]-6-[5-({[2-(metilsulfonil)= etil]amino}metil)-2-furil]quinazolin-4-amina

C₂₉H₂₆ClFN₄O₄S

lomeguatribum

lomeguatrib

6-(4-bromothenyloxy)-7H-purin-2-amine

lomeguatrib

6-[(4-bromothiophen-2-yl)methoxy]-7H-purin-2-amine

lomeguatrib

6-(4-bromoteniloxi)-7H-purin-2-amina

C₁₀H₈BrN₅OS

odiparcilum

odiparcil

4-methyl-7-(5-thio-β-D-xylopyranosyloxy)-2H-chromen-2-one

odiparcil

4-méthyl-7-[(5-thio-β-D-xylopyranosyl)oxy]-2H-1-benzopyran-2-one

odiparcilo

4-metil-7-(5-tio-β-D-xilopiranosiloxi)-2H-cromen-2-ona

C₁₅H₁₆O₆S

omigananum

omiganan

L-isoleucyl-L -leucyl-L -arginyl-L-tryptophyl-L-prolyl-L -tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L -arginyl-L-arginyl-L-lysinamide

omiganan

L-isoleucyl-L -leucyl-L -arginyl-L-tryptophyl-L-prolyl-L -tryptophyl-L-tryptophyl-L-prolyl-L-tryptophyl-L -arginyl-L-arginyl-L-lysinamide

omiganán

L-isoleucil-L -leucil-L-arginil-L-triptofil-L -prolil-L-triptofil-L-triptofil-L-prolil-L-triptofil-L -arginil-L-arginil-L-lisinamida

C₉₀H₁₂₇N₂₇O₁₂

pactimibum

pactimibe

[7-(2,2-dimethylpropanamido)-4,6-dimethyl-1-octylindolin-5-yl]acetic acid

pactimibe

acide [7-[(2,2-diméthylpropanoyl)amino]-4,6-diméthyl-1-octyl-2,3-dihydro-1H-indol-5-yl]acétique

pactimiba

ácido [7-(2,2-dimetilpropanamido)-4,6-dimetil-1-octilindolin-5-il] acético

C₂₅H₄₀N₂O₃

patupilonum

patupilone

(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentamethyl-3-[(1E)-1-(2-methyl-1,3-thiazol-4-yl)prop-1-en-2-yl]-4,17-dioxabicyclo[14.1.0]heptadecane-5,9-dione

patupilone

(1S,3S,7S,10R,11S,12S,16R)-7,11-dihydroxy-8,8,10,12,16-pentaméthyl-3-[(1E)-1-méthyl-2-(2-méthylthiazol-4-yl)éthényl]-4,17-dioxabicyclo[14.1.0]heptadécane-5,9-dione

patupilona

(1S,3S,7S,10R,11S,12S,16R)-7,11-dihidroxi-8,8,10,12,16-pentametil-3-[(1E)-1-(2-metil-1,3-tiazol-4-il)prop-1-en-2-il]-4,17-dioxabiciclo[14.1.0]heptadecano-5,9-diona

C₂₇H₄₁NO₆S

pertuzumabum

pertuzumab

immunoglobulin G1, anti-(human ν (receptor)) (human-mouse monoclonal 2C4 heavy chain), disulfide with human-mouse monoclonal 2C4 κ-chain, dimer

pertuzumab

immunoglobuline G1, anti-(récepteur ν humain), dimère du disulfure entre la chaîne κ et la chaîne lourde de l’anticorps monoclonal de souris humanisé 2C4

pertuzumab

inmunoglobulina G1, anti-(receptor ν humano), dímero del disulfuro entre la cadena κ y la cadena pesada del anticuerpo monoclonal humanizado de ratón 2C4

pixantronum

pixantrone

6,9-bis[(2-aminoethyl)amino]benzo[g]isoquinoline-5,10-dione

pixantrone

6,9-bis[(2-aminoéthyl)amino]benzo[g]isoquinoléine-5,10-dione

pixantrona

6,9-bis[(2-aminoetil)amino]benzo[g]isoquinolina-5,10-diona

C₁₇H₁₉N₅O₂

pritumumabum

pritumumab

immunoglobulin G, anti-(human vimentin) (human monoclonal CLN G11 γ1-chain), disulfide with human monoclonal CLN G11 κ-chain, dimer

pritumumab

immunoglobuline G, anti-(vimentine humaine); dimère du disulfure entre la chaîne γ1 et la chaîne κ de l'anticorps monoclonal humain CLN H11

pritumumab

inmunoglobulina G, anti-(vimentina humana); dímero del disulfuro entre la cadena γ1 y la cadena κ del anticuerpo monoclonal humano CLN H11

C₆₄₄₀H₉₉₆₈N₁₇₀₈O₂₀₁₆S₄₂

ralfinamidum

ralfinamide

(2S)-2-[4-(2-fluorobenzyloxy)benzylamino]propanamide

ralfinamide

(+)-(2S)-2-[[4-[(2-fluorobenzyl)oxy]benzyl]amino]propanamide

ralfinamida

(+)-(2S)-2-[4-(2-fluorobenciloxi)bencilamino]propanamide

C₁₇H₁₉FN₂O₂

rebimastatum

rebimastat

N-[(2S)-2-sulfanyl-4-(3,4,4-trimethyl-2,5-dioxoimidazolidin-1-yl)butanoyl]-L-leucyl-N¹,3-dimethyl-L -valinamide

rébimastat

(2S)-N-[(1S)-2,2-diméthyl-1-(méthylcarbamoyl)propyl]-4-méthyl-2-[[(2S)-2-sulfanyl-4-(3,4,4-triméthyl-2,5-dioxoimidazolidin-1-yl)butanoyl]amino]pentanamide

rebimastat

N-[(2S) -2-sulfanil-4-(3,4,4-trimetil-2,5-dioxoimidazolidin-1-il)butanoil]-L-leucil-N¹,3-dimetil-L-valinamida

C₂₃H₄₁N₅O₅S

segesteronum

segesterone

17-hydroxy-16-methylene-19-norpregn-4-ene-3,20-dione

ségestérone

17-hydroxy-16-méthylène-19-norprégn-4-ène-3,20-dione

segesterona

17-hidroxi-16-metileno-19-norpregn-4-eno-3,20-diona

C₂₁H₂₈O₃

semapimodum

semapimod

N,N'-bis{3,5-bis[1-(carbamimidoylhydrazono)ethyl]phenyl}= decanediamide

sémapimod

N,N'-bis[3,5-bis[ N-(carbamimidoylamino)acétimidoyl]phényl]= décanediamide

semapimod

N,N'-bis{3,5-bis[1-(carbamimidoilhidrazono)etil]fenil}= decanodiamida

C₃₄H₅₂N₁₈O₂

sufugolixum

sufugolix

5-{[benzyl(methyl)amino]methyl}-1-(2,6-difluorobenzyl)-6-[4-(3-methoxyureido)phenyl]-3-phenylthieno[2,3-d]pyrimidine-2,4(1H,3H)-dione

sufugolix

1-[4-[5-[(benzylméthylamino)méthyl]-1-(2,6-difluorobenzyl)-2,4-dioxo-3-phényl-1,2,3,4-tétrahydrothiéno[2,3-d]pyrimidin-6-yl]phényl]-3-méthoxyurée

sufugolix

5-{[bencil(metil)amino]metil}-1-(2,6-difluorobencil)-6-[4-(3-metoxiureido)fenil]-3-feniltieno[2,3-d]pirimidina-2,4(1H,3H)-diona

C₃₆H₃₁F₂N₅O₄S

tacapenemum

tacapenem

(+)-(4R,5S,6S)-6-[(1R)-1-hydroxyethyl]-4-methyl-7-oxo-3-[[(3R)-5-oxopyrrolidin-3-yl]sulfanyl]-1-azabicyclo[3.2.0]hept-2-ene-2-carboxylic acid

tacapénem

(+)-acide (4R,5S,6S)-6-[(1R)-1-hydroxyéthyl]-4-méthyl-7-oxo-3-[[(3R)-5-oxopyrrolidin-3-yl]sulfanyl]-1-azabicyclo[3.2.0]hept-2-ène-2-carboxylique

tacapenem

(+)-ácido (4R,5S,6S)-6-[(1R)-1-hidroxietil]-4-metil-7-oxo-3-[[(3R)-5-oxopirrolidin-3-il]sulfanil]-1-azabiciclo[3.2.0]hept-2-eno-2-carboxílico

C₁₄H₁₈N₂O₅S

tafluprostum

tafluprost

isopropyl (5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phenoxybut-1-enyl]-3,5-dihydroxycyclopentyl}hept-5-enoate

tafluprost

(5Z)-7-[(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-phénoxybut-1-ényl]-3,5-dihydroxycyclopentyl]hept-5-énoate de 1-méthyléthyle

tafluprost

(5Z)-7-{(1R,2R,3R,5S)-2-[(1E)-3,3-difluoro-4-fenoxibut-1-enil]-3,5-dihidroxiciclopentil}hept-5-enoato de isopropilo

C₂₅H₃₄F₂O₅

talizumabum

talizumab

immunoglobulin G, anti-(human immunoglobulin E Fc region) (human-mouse monoclonal Hu901 γ-chain), disulfide with human-mouse monoclonal Hu901 κ-chain, dimer

talizumab

immunoglobuline G, anti-(région Fc de l’immunoglobuline E humaine), dimère du disulfure entre la chaîne κ et la chaîne γ de l’anticorps monoclonal de souris humanisé Hu901

talizumab

inmunoglobulina G, anti-(región Fc de la inmunoglobulina E humana), dímero del disulfuro entre la cadena κ y la cadena γ del anticuerpo monoclonal humanizado de ratón Hu901

technetium (99mTc) nitridocadum

technetium (99mTc) nitridocade

(SPY-5-21)-bis[ethoxy(ethyl)dithiocarbamato-κS, κS']nitrido=[^99mTc]technetium

technétium (99mTc) nitridocade

(SPY-5-21)-bis(éthoxyéthyldithiocarbamato-κS, κS')nitrido=[^99mTc]technétium

tecnecio (99mTc) nitridocado

(SPY-5-21)-bis(etoxietilditiocarbamato-κS, κS')nitrido[^99mTc]tecnecio

C₁₀H₂₀N₃O₂S₄^99mTc

tesofensinum

tesofensine

(1R,2R,3S,5S)-3-(3,4-dichlorophenyl)-2-(ethoxymethyl)-8-methyl-8-azabicyclo[3.2.1]octane

tésofensine

(1R,2R,3S,5S)-3-(3,4-dichlorophényl)-2-(éthoxyméthyl)-8-méthyl-8-azabicyclo[3.2.1]octane

tesofensina

(1R,2R,3S,5S)-3-(3,4-diclorofenil)-2-(etoximetil)-8-metil-8-azabiciclo[3.2.1]octano

C₁₇H₂₃Cl₂NO

tifenazoxidum

tifenazoxide

6-chloro-N-(1-methylcyclopropyl)-1,1-dioxo-1,4-dihydro-1λ⁶-thieno[3,2-e][1,2,4]thiadiazin-3-amine

tifénazoxide

1,1-dioxyde de 6-chloro-N-(1-méthylcyclopropyl)-4H-thiéno[3,2-e]-1,2,4-thiadiazin-3-amine

tifenazóxido

1,1-dióxido de 6-cloro-N-(1-metilciclopropil)-4H-tieno[3,2-e]-1,2,4-tiadiazin-3-amina

C₉H₁₀ClN₃O₂S₂

tisocalcitatum

tisocalcitate

isopropyl (1S,3R,5Z,7E,22E,24R)-1,3,24-trihydroxy-9,10-secocholesta-5,7,10(19),22-tetraene-25-carboxylate

tisocalcitate

(5Z,7E,22E,24R)-1α,3β,24-trihydroxy-9,10-sécocholesta-5,7,10(19),22-tétraène-25-carboxylate de 1-méthyléthyle

tisocalcitato

(1S,3R,5Z,7E,22E,24R)-1,3,24-trihidroxi-9,10-secocolesta-5,7,10(19),22-tetraeno-25-carboxilato de isopropilo

C₃₁H₄₈O₅

ulifloxacinum

ulifloxacin

(1RS)-6-fluoro-1-methyl-4-oxo-7-(piperazin-1-yl)-4H-[1,3]thiazeto[3,2-a]quinoline-3-carboxylic acid

ulifloxacin

acide (1RS)-6-fluoro-1-méthyl-4-oxo-7-(pipérazin-1-yl)-4H-[1,3]thiazéto[3,2-a]quinoléine-3-carboxylique

ulifloxacino

ácido (1RS)-6-fluoro-1-metil-4-oxo-7-(piperazin-1-il)-4H-[1,3]tiazeto[3,2-a]quinolina-3-carboxílico

C₁₆H₁₆FN₃O₃S

vareniclinum

varenicline

7,8,9,10-tetrahydro-6H-6,10-methanoazepino[4,5-g]quinoxaline

varénicline

(6R,10S)-7,8,9,10-tétrahydro-6,10-méthano-6H-pyrazino[2,3-h][3]benzazépine

vareniclina

7,8,9,10-tetrahidro-6H-6,10-metanoazepino[4,5-g]quinoxalina

C₁₃H₁₃N₃

p. 158

suprimase

insértese

metodilazina

metdilazina

lauromacrogolum 400

p. 427

lauromacrogol 400

replace the description by the following:
polyethylene glycol monododecyl ether, the name is followed by a number (400) corresponding approximately to the average molecular mass of the polyethylene glycol portion

p. 474

lauromacrogol 400

remplacer la description par la suivante:
α-dodécyl-ω-hydroxypoly(oxyéthylène), la masse moyenne de la partie macrogol (#44n+18) est indiquée entre parenthèses après la dénomination

p. 340

lauromacrogol 400

sustitúyase la descripción por la siguiente:
éter monododecílico del polietilen glicol, al nombre le sigue un número (400) que corresponde aproximadamente a la masa molecular media de la fracción polietilenglicol

p. 194

supprimer

insérer

pregabaline

prégabaline

Procedure and Guiding Principles / Procédure et Directives / Procedimientos y principios generales

The text of the Procedures for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances and General Principles for Guidance in Devising International Nonproprietary Names for Pharmaceutical Substances will be reproduced in uneven numbers of proposed INN lists only.

Les textes de la Procédure à suivre en vue du choix de dénominations communes internationales recommandées pour les substances pharmaceutiques et des Directives générales pour la formation de dénominations communes internationales applicables aux substances pharmaceutiques seront publiés seulement dans les numéros impairs des listes des DCIs proposées.

El texto de los Procedimientos de selección de denominaciones comunes internacionales recomendadas para las sustancias farmacéuticas y de los Principios generales de orientación para formar denominaciones comunes internacionales para sustancias farmacéuticas aparece solamente en los números impares de las listas de DCI propuestas.